It seems that the ghost of the US Food and Drug Administration
(FDA) probe has stopped haunting MDS Pharma as the firm posted
encouraging financial results in the third quarter.
AstraZeneca (AZ) is to assist Biovator in the development of its
in vitro test for identifying potential allergens that
could replace many experiments on animals.
German firm Biotest has bought up Nabi Biopharmaceuticals biologics
division in a multi-million Euro deal, less than three months after
the unit was created following Nabi restructuring efforts.
Irish start-up Crospon has licensed a 'smart' drug delivery
skin patch technology from HP Labs that uses inkjet printing
technology to deliver drugs under the skin.
Averion has formed a new partnership in South America's clinical
trial hotspot Brazil - as it continues to tip-toe beyond North
America and Europe into emerging markets.
Manufacturing problems hindering production of MedImmune's
intranasal flu vaccine FluMist have finally been resolved at the
company's Liverpool, UK facility, with doses on track to be
available for this year's flu season.
King Pharmaceuticals has ended its alliance with Palatin
Technologies, shortly after regulators raised 'serious concerns'
over the first-in-class erectile dysfunction drug which was the
subject of the collaboration.
Denmark-based Chr. Hansen has sold its excipients and coating
division to US company Colorcon for an undisclosed sum to
concentrate on its food business.
Ablynx, one of the two main players in the miniature antibody
sector, has signed 'by far' the biggest deal in its history, to
help Boehringer Ingelheim develop up to ten so called 'Nanobodies'.
Anasys Instruments has launched the world's first easy-to-use local
thermal analyser which promises to help pharmaceutical companies'
quality control (QC) of drug coatings and formulations.
French pharmaceutical firm LFB has announced its plans to
incrementally acquire fellow biotech company MAbgene through
the development of a new entity for a total of €6m.
Hope may be on the horizon in the quest for a preventative
hepatitis C virus (HCV) vaccine after scientists said they have
been able to identify and characterise the antibody responses to
the virus.
Indian IT firm Tata Consultancy Services (TCS) has bagged its
second high profile pharma outsourcing deal this year with a new
multi-year contract with Swiss drug maker Roche.
Isis Pharmaceuticals has initiated a Phase I safety study for its
first-in-class antisense drug that aims to control blood glucose
levels in patients with Type II diabetes.
US biopharmaceutical company CytoGenix has announced breaking
ground on a new $3.8m facility to expand the company's
manufacturing capability of synthetic DNA.
Shire and Noven Pharmaceuticals have announced the voluntary
withdrawal of a limited amount of Attention Deficit Hyperactivity
Disorder (ADHD) transdermal patches following reports of a
mechanical problem when applying the patch.
Britain's Eden Biodesign has been selected by Cancer Research UK as
the beneficiary of two new biomanufacturing contracts as its
biomanufacturing business continues to grow.
US biotech Medarex has announced it has extended its licensing deal
with Centocor, giving the firm continued access to its antibody
production technology.
Novo Nordisk, Rheosciences, ImClone, Omrix Biopharmaceuticals,
Biogen Idec and Human Genome Sciences, have all had people on the
move in the biotech world.
Acambis has had its smallpox vaccine approved by the US, coming one
step closer to closing another supply contract for the US Strategic
National Stockpile.
J&J has expressed its concern over patient safety as Novartis'
subsidiary Sandoz has received the green light from the European
Commission to launch the first epoetin alfa biosimilar on the EU
market.
The end of the tunnel seems to be getting closer for South
African manufacturer Enaleni as the firm confirmed it will resume
production in its recently closed Durban facility in the next ten
days.
A contract research organisation (CRO) is offering a unique
toxicity screening service using zebrafish as a model for assessing
drug effects on cardiac function.
US researchers have shown certain organic solvents can be used to
selectively extract therapeutic proteins from host bacteria,
avoiding the need for cell lysis and increasing product purity by a
factor of five.
Positive results from a Phase II trial have shown that Eli Lilly's
latest antipsychotic drug acts on a new target and avoids key
adverse effects caused by other antipsychotics.
Boehringer Ingelheim is voluntarily recalling all worldwide
products containing clobutinol hydrochloride, which has been on the
market for 46 years, following a report questioning the drug's
safety.
Reformulations of pseudoephedrine- and ephedrine-containing drugs
in the UK look unlikely following the announcement of less extreme
restrictions on the sale of the pharmaceuticals.
Merck Serono's new and improved version of its blockbuster multiple
sclerosis (MS) drug Rebif (interferon beta-1a) has been approved in
the EU, providing a little added protection to the company's MS
franchise.
New research has shown that silica nanowires can be used to deliver toxic agents into both human and bovine epithelial cell lines, opening up new options for drug targeting and delivery.
LabTechnologist.com brings you its periodic round up of new product
releases and product news, with new offerings from Aura, Horiba
Jobin Yvon, Integra, Metrohm, Millipore, Promega, Roche and Thermo
Fisher Scientific.
In the latest phase of growth at chemical firm SAFC's flagship high
potency active pharmaceutical ingredients (HPAPIs) facility in
Madison, Wisconsin, the site will be treated to another
multi-million dollar expansion and new...
Two big players in the early stage contract research organisation
(CRO) arena have announced this week they are expanding their
preclinical capabilities in Canada as demand for preclinical
testing is rising.
PDL Biopharma has seen a week of drama after announcing a
restructure that left its key investor calling for the company
chairman to resign, a week after its CEO also decided to step
down after similar pressure.
Micromet is sticking to its research into cell adhesion antibodies
to treat breast cancer and other tumours, hoping it will have more
luck than GlaxoSmithKline and Centocor's failed attempt.
Sigma-Aldrich has launched a new technology that promises to
dramatically simplify and speed-up high-throughput (HT) RNAi
screening of the human kinome.
Lonza's $200m (€147m) investment in China is continuing to shape up
as the firm announced its new small-scale exclusive synthesis
manufacturing plant will be up and running next month.
